Zymeworks ZYME
Valuation
Multiples measured against the stock's own five-year history
Near the top of its 5-year range · 100th percentile, 5-year average -6.8x
#2576 of 2993 stocks by PE (1 = cheapest)
Near the top of its 5-year range · 87th percentile, 5-year average 4.0x
#4717 of 5330 stocks by PB (1 = cheapest)
Below its usual level · 20th percentile, 5-year average 14.1x
#4240 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 7.01 | – | 4.01 | 87% (pricier than usual) | #4717 of 5330 (1 = cheapest) |
| PE | 49.51 | 33.53 | -6.84 | 100% (pricier than usual) | #2576 of 2993 (1 = cheapest) |
| PS | 6.81 | 5.08 | 14.09 | 20% (cheaper than usual) | #4240 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on ZYME.
Sign in to join the discussion.